The number of patients with metastatic castration-resistant prostate cancer (mCRPC) is expected to increase due to the long life expectancy of those with advanced disease who are also more commonly diagnosed today because of stage migration. Several compounds are available for treating these patients.
Factors influencing survival in metastatic castration-resistant prostate cancer therapy
Marchioni, Michele;Schips, Luigi
2022-01-01
Abstract
The number of patients with metastatic castration-resistant prostate cancer (mCRPC) is expected to increase due to the long life expectancy of those with advanced disease who are also more commonly diagnosed today because of stage migration. Several compounds are available for treating these patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
iery_a_2114458_sm0944.pdf
non disponibili
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
113.37 kB
Formato
Adobe PDF
|
113.37 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
